{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:21:13Z","timestamp":1787610073013,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"35","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,15]]},"DOI":"10.1038\/s41388-026-03915-5","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:16:29Z","timestamp":1784859389000},"page":"3660-3672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DTX3 promotes anti-tumor immunity by inducing PD-L1 ubiquitination and is suppressed by p65\/miR-222 in bladder cancer"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-2058","authenticated-orcid":false,"given":"Yu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaYu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhun","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuanZhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3577-7069","authenticated-orcid":false,"given":"YuanZhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiYong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8211-2721","authenticated-orcid":false,"given":"YiJun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"3915_CR1","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee D, Cho M, Kim E, Seo Y, Cha JH. PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024;32:4235\u201355.","journal-title":"Mol Ther"},{"key":"3915_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02400-z","volume":"24","author":"K Mandal","year":"2025","unstructured":"Mandal K, Barik GK, Santra MK. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. Mol Cancer. 2025;24:246.","journal-title":"Mol Cancer"},{"key":"3915_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"3915_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.humpath.2018.06.028","volume":"81","author":"JJ Davick","year":"2018","unstructured":"Davick JJ, Frierson HF, Smolkin M, Gru AA. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases. Hum Pathol. 2018;81:184\u201391.","journal-title":"Hum Pathol"},{"key":"3915_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02095-8","volume":"23","author":"Q Liu","year":"2024","unstructured":"Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: the \u201call-around warrior\u201d in immunotherapy. Mol Cancer. 2024;23:183.","journal-title":"Mol Cancer"},{"key":"3915_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1591379","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, He M, Li J, Li L. Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review. Front Immunol. 2025;16:1591379.","journal-title":"Front Immunol"},{"key":"3915_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23:108.","journal-title":"Mol Cancer"},{"key":"3915_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287\u2013305.","journal-title":"Nat Rev Clin Oncol"},{"key":"3915_CR9","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.gendis.2022.01.002","volume":"10","author":"P Ding","year":"2023","unstructured":"Ding P, Ma Z, Fan Y, Feng Y, Shao C, Pan M, et al. Emerging role of ubiquitination\/deubiquitination modification of PD-1\/PD-L1 in cancer immunotherapy. Genes Dis. 2023;10:848\u201363.","journal-title":"Genes Dis"},{"key":"3915_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.ymthe.2020.12.032","volume":"29","author":"X Hu","year":"2021","unstructured":"Hu X, Wang J, Chu M, Liu Y, Wang ZW, Zhu X. Emerging role of ubiquitination in the regulation of PD-1\/PD-L1 in cancer immunotherapy. Mol Ther. 2021;29:908\u201319.","journal-title":"Mol Ther"},{"key":"3915_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91\u20135.","journal-title":"Nature"},{"key":"3915_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.835603","volume":"12","author":"M Wei","year":"2022","unstructured":"Wei M, Mo Y, Liu J, Zhai J, Li H, Xu Y, et al. Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation. Front Oncol. 2022;12:835603.","journal-title":"Front Oncol"},{"key":"3915_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell\u2013mediated bladder cancer immune surveillance. Cancer Res. 2022;82:114\u201329.","journal-title":"Cancer Res"},{"key":"3915_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107178","volume":"179","author":"YJ Zhang","year":"2023","unstructured":"Zhang YJ, Xiong SP, Yang YZ, Fu S, Wang TM, Suster DI, et al. Clinicopathologic features, tumor immune microenvironment and genomic landscape of EBV-related and EBV-unrelated poorly differentiated nonkeratinizing squamous cell carcinoma of the thymus. Lung Cancer. 2023;179:107178.","journal-title":"Lung Cancer"},{"key":"3915_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41588-019-0569-6","volume":"52","author":"J Chen","year":"2020","unstructured":"Chen J, Yang H, Teo ASM, Amer LB, Sherbaf FG, Tan CQ, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020;52:177\u201386.","journal-title":"Nat Genet"},{"key":"3915_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114529","volume":"153","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Sun Q, Chen Y, Wang J, Chen Y, Yang Y, et al. DTX3 suppresses bladder cancer cell invasion and metastasis by inhibiting the Notch signaling pathway. Int Immunopharmacol. 2025;153:114529.","journal-title":"Int Immunopharmacol"},{"key":"3915_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1094598","volume":"5","author":"S Hong","year":"2016","unstructured":"Hong S, Chen N, Fang W, Zhan J, Liu Q, Kang S, et al. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK-positive NSCLC: Implication for optional anti-PD-1\/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology. 2016;5:e1094598.","journal-title":"Oncoimmunology"},{"key":"3915_CR18","doi-asserted-by":"publisher","first-page":"7796","DOI":"10.1111\/jcmm.16674","volume":"25","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Hu Y, Wang H, Zhao Z, Jiang X, Zhang Y, et al. Ring finger protein 19A is overexpressed in non-small cell lung cancer and mediates p53 ubiquitin-degradation to promote cancer growth. J Cell Mol Med. 2021;25:7796\u2013808.","journal-title":"J Cell Mol Med"},{"key":"3915_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2026.116169","volume":"171","author":"Y Cheng","year":"2026","unstructured":"Cheng Y, Li S, Li X, Xue J, Hao M, Zhou L, et al. RNF19A facilitates gastric cancer progression by regulating the Hippo\/YAP axis. Int Immunopharmacol. 2026;171:116169.","journal-title":"Int Immunopharmacol"},{"key":"3915_CR20","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1093\/nar\/gkr006","volume":"39","author":"S Galardi","year":"2011","unstructured":"Galardi S, Mercatelli N, Farace MG, Ciafre SA. NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res. 2011;39:3892\u2013902.","journal-title":"Nucleic Acids Res"},{"key":"3915_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00428-007-0560-y","volume":"452","author":"G Levidou","year":"2008","unstructured":"Levidou G, Saetta AA, Korkolopoulou P, Papanastasiou P, Gioti K, Pavlopoulos P, et al. Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder. Virchows Arch. 2008;452:295\u2013304.","journal-title":"Virchows Arch"},{"key":"3915_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584626","volume":"11","author":"F Antonangeli","year":"2020","unstructured":"Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F. Regulation of PD-L1 expression by NF-\u03baB in cancer. Front Immunol. 2020;11:584626.","journal-title":"Front Immunol"},{"key":"3915_CR23","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/cells12131680","volume":"12","author":"P Scalia","year":"2023","unstructured":"Scalia P, Williams SJ, Suma A, Carnevale V. The DTX protein family: an emerging set of E3 ubiquitin ligases in cancer. Cells. 2023;12:1680.","journal-title":"Cells"},{"key":"3915_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/genetics\/136.2.585","volume":"136","author":"I Busseau","year":"1994","unstructured":"Busseau I, Diederich RJ, Xu T, Artavanis-Tsakonas S. A member of the Notch group of interacting loci, deltex encodes a cytoplasmic basic protein. Genetics. 1994;136:585\u201396.","journal-title":"Genetics"},{"key":"3915_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc0418","volume":"6","author":"C Chatrin","year":"2020","unstructured":"Chatrin C, Gabrielsen M, Buetow L, Nakasone MA, Ahmed SF, Sumpton D, et al. Structural insights into ADP-ribosylation of ubiquitin by Deltex family E3 ubiquitin ligases. Sci Adv. 2020;6:eabc0418.","journal-title":"Sci Adv"},{"key":"3915_CR26","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s11033-021-06916-7","volume":"49","author":"H Xu","year":"2022","unstructured":"Xu H, Liang S, Hu J, Liu W, Dong Z, Wei S. Deltex E3 ubiquitin ligase 3 inhibits colorectal cancer cell growth and regulates cell cycle progression via upregulating E2F transcription factor 1. Mol Biol Rep. 2022;49:1661\u201368.","journal-title":"Mol Biol Rep"},{"key":"3915_CR27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.7150\/jca.48141","volume":"12","author":"L Wang","year":"2021","unstructured":"Wang L, Huang Y, Liu C, Guo M, Ma Z, He J, et al. Deltex3 inhibits epithelial- mesenchymal transition in papillary thyroid carcinoma via promoting ubiquitination of XRCC5 to regulate the AKT signal pathway. J Cancer. 2021;12:860\u201373.","journal-title":"J Cancer"},{"key":"3915_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cas.14288","volume":"111","author":"XY Ding","year":"2020","unstructured":"Ding XY, Hu HY, Huang KN, Wei RQ, Min J, Qi C, et al. Ubiquitination of NOTCH2 by DTX3 suppresses the proliferation and migration of human esophageal carcinoma. Cancer Sci. 2020;111:489\u2013501.","journal-title":"Cancer Sci"},{"key":"3915_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/2326-6066.CIR-17-0249","volume":"6","author":"BL Horton","year":"2018","unstructured":"Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF. Intratumoral CD8+ T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity. Cancer Immunol Res. 2018;6:14\u201324.","journal-title":"Cancer Immunol Res"},{"key":"3915_CR30","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1111\/j.1600-6143.2007.01999.x","volume":"7","author":"A Habicht","year":"2007","unstructured":"Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, et al. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transpl. 2007;7:2683\u201392.","journal-title":"Am J Transpl"},{"key":"3915_CR31","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y, et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell. 2022;185:4049\u201366.e25.","journal-title":"Cell"},{"key":"3915_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.","journal-title":"Mol Cancer"},{"key":"3915_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02176-8","volume":"23","author":"M Jin","year":"2024","unstructured":"Jin M, Fang J, Peng J, Wang X, Xing P, Jia K, et al. PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23:266.","journal-title":"Mol Cancer"},{"key":"3915_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217498","volume":"612","author":"TA Lee","year":"2025","unstructured":"Lee TA, Tsai EY, Liu SH, Chou WC, Hsu Hung SD, Chang CY, et al. Regulation of PD-L1 glycosylation and advances in cancer immunotherapy. Cancer Lett. 2025;612:217498.","journal-title":"Cancer Lett"},{"key":"3915_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007313","volume":"11","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zeng L, Wang M, Yang Z, Zhang H, Gao L, et al. RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination. J Immunother Cancer. 2023;11:e007313.","journal-title":"J Immunother Cancer"},{"key":"3915_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34346-x","volume":"13","author":"C Shi","year":"2022","unstructured":"Shi C, Wang Y, Wu M, Chen Y, Liu F, Shen Z, et al. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nat Commun. 2022;13:6951.","journal-title":"Nat Commun"},{"key":"3915_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007415","volume":"11","author":"Z Sun","year":"2023","unstructured":"Sun Z, Mai H, Xue C, Fan Z, Li J, Chen H, et al. Hsa-LINC02418\/mmu-4930573I07Rik, regulated by METTL3, dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination. J Immunother Cancer. 2023;11:e007415.","journal-title":"J Immunother Cancer"},{"key":"3915_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.canlet.2021.08.008","volume":"520","author":"S-R Ho","year":"2021","unstructured":"Ho S-R, Lee Y-C, Ittmann MM, Lin F-T, Chan KS, Lin W-C. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. Cancer Lett. 2021;520:344\u201360.","journal-title":"Cancer Lett"},{"key":"3915_CR39","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1158\/0008-5472.CAN-15-0457","volume":"75","author":"JJ Zhao","year":"2015","unstructured":"Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, et al. Targeting the miR-221-222\/PUMA\/BAK\/BAX pathway abrogates dexamethasone resistance in multiple myeloma. Cancer Res. 2015;75:4384\u201397.","journal-title":"Cancer Res"},{"key":"3915_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3892\/ijo.2021.5200","volume":"58","author":"D Wang","year":"2021","unstructured":"Wang D, Sang Y, Sun T, Kong P, Zhang L, Dai Y, et al. Emerging roles and mechanisms of microRNA\u2011222\u20113p in human cancer (Review). Int J Oncol. 2021;58:20.","journal-title":"Int J Oncol"},{"key":"3915_CR41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/jcmm.12760","volume":"20","author":"LP Zeng","year":"2016","unstructured":"Zeng LP, Hu ZM, Li K, Xia K. miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A\/Akt\/mTOR Axis in bladder cancer cells. J Cell Mol Med. 2016;20:559\u201367.","journal-title":"J Cell Mol Med"},{"key":"3915_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1477-7819-12-241","volume":"12","author":"DQ Zhang","year":"2014","unstructured":"Zhang DQ, Zhou CK, Jiang XW, Chen J, Shi BK. Increased expression of miR-222 is associated with poor prognosis in bladder cancer. World J Surg Oncol. 2014;12:241.","journal-title":"World J Surg Oncol"},{"key":"3915_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/srep40723","volume":"7","author":"X Cui","year":"2017","unstructured":"Cui X, Shen D, Kong C, Zhang Z, Zeng Y, Lin X, et al. NF-\u03baB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo. Sci Rep. 2017;7:40723.","journal-title":"Sci Rep"},{"key":"3915_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1158\/2159-8290.CD-11-0260","volume":"1","author":"BB Aggarwal","year":"2011","unstructured":"Aggarwal BB, Sung B. NF-\u03baB in cancer: a matter of life and death. Cancer Discov. 2011;1:469\u201371.","journal-title":"Cancer Discov"},{"key":"3915_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri1703","volume":"5","author":"M Karin","year":"2005","unstructured":"Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749\u201359.","journal-title":"Nat Rev Immunol"},{"key":"3915_CR46","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.7150\/thno.69444","volume":"12","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Jin X, Yu H, Qin G, Pan P, Zhao J, et al. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Theranostics. 2022;12:2080\u201394.","journal-title":"Theranostics"},{"key":"3915_CR47","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1002\/iid3.864","volume":"11","author":"X Zeng","year":"2023","unstructured":"Zeng X, Tang X, Chen X, Wen H. RNF182 induces p65 ubiquitination to affect PDL1 transcription and suppress immune evasion in lung adenocarcinoma. Immun Inflamm Dis. 2023;11:e864.","journal-title":"Immun Inflamm Dis"},{"key":"3915_CR48","doi-asserted-by":"publisher","first-page":"15676","DOI":"10.1002\/cam4.6172","volume":"12","author":"W Wu","year":"2023","unstructured":"Wu W, Chen L, Jia G, Tang Q, Han B, Xia S, et al. Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3\/NF-kB pathway in muscle-invasive bladder cancer. Cancer Med. 2023;12:15676\u201390.","journal-title":"Cancer Med"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03915-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03915-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:03:18Z","timestamp":1787608998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03915-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":48,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026,9,15]]}},"alternative-id":["3915"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03915-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"We confirm that all methods were performed in accordance with the relevant guidelines and regulations. Research involving human participants was conducted in accordance with applicable laws, regulations, guidelines, and ethical principles such as those outlined in the Belmont Report. All clinical samples and animal experiments involved in this study were approved by the Ethics Committee of Sun Yat-sen University Cancer Center.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}